|
注册号: Registration number: |
ChiCTR2400090627 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-10 11:02:13 |
|
注册时间: Date of Registration: |
2024-10-10 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
慢乙肝病理的智能模型 |
|
Public title: |
Intelligent model of chronic viral hepatitis B pathology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于深度学习建立并验证识别慢乙肝肝脏病理免疫模式、严重程度的智能模型 |
|
Scientific title: |
Based on deep learning, an intelligent model to identify pathological immune pattern and severity of chronic hepatitis B liver was established and verified |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵新颜 |
研究负责人: |
赵新颜 |
|
Applicant: |
Zhao Xinyan |
Study leader: |
Zhao Xinyan |
|
申请注册联系人电话: Applicant telephone: |
+86 13801001732 |
研究负责人电话:
Study leader's |
+86 10 63138458 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhao_xinyan@ccmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
zhao_xinyan@ccmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区永安路95号北京友谊医院西门科研一号楼 |
研究负责人通讯地址: |
北京市西城区永安路95号 |
|
Applicant address: |
Building 1, West Gate Scientific Research, Beijing Friendship Hospital, 95 Yongan Road, Xicheng Dist |
Study leader's address: |
No.95 Yongan Road,Xicheng District,Beijing,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属北京友谊医院 |
||
|
Applicant's institution: |
Beijing Friendship Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京友谊医院 |
||
|
Affiliation of the Leader: |
Beijing Friendship Hospital ,Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-P2-042-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京友谊医院生命伦理委员会 |
||
|
Name of the ethic committee: |
Bioethics Committee of Beijing Friendship Hospital Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-22 00:00:00 | ||
|
伦理委员会联系人: |
李悦 |
||
|
Contact Name of the ethic committee: |
Li Yue |
||
|
伦理委员会联系地址: |
北京市西城区永安路95号 |
||
|
Contact Address of the ethic committee: |
No.95 Yongan Road,Xicheng District,Beijing,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 63139006 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
13661202501@163.com |
|
研究实施负责(组长)单位: |
首都医科大学附属北京友谊医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Friendship Hospital ,Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区永安路95号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.95 Yongan Road,Xicheng District,Beijing,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
病原学与防疫技术体系研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
慢性乙型病毒性肝炎 |
||||||||||||||||||||||
|
Target disease: |
Chronic hepatitis B |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
建立并验证一种基于医学认知的人工智能模型,识别慢乙肝肝脏病理切片中的病变及其部位性质和程度、炎症细胞特点,进而分析描述慢乙肝肝脏病理模式,包括炎症分级、纤维化分期,联系临床信息,辅助判断临床严重程度。 |
||||||||||||||||||||||
|
Objectives of Study: |
Establish and verify an artificial intelligence model based on medical cognition to identify lesions, their site nature and degree, and the characteristics of inflammatory cells in pathological sections of chronic hepatitis B liver, and then analyze and describe the immune pattern of chronic hepatitis B liver pathology, and associate clinical information to assist in judging clinical severity. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.合并其他原发肝脏疾病:遗传代谢性肝病、先天性发育异常性肝病等;酒精性肝病,即饮酒时间大于5年,饮酒量:男>40g/d,女>20g/d;自身免疫性肝炎的简化表评分≥6分或复杂表评分≥10分,或与自身免疫性肝炎无法鉴别; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Combined with other primary liver diseases: hereditary metabolic liver disease, congenital dysplastic liver disease, etc. Alcoholic liver disease, that is, drinking time greater than 5 years, alcohol consumption: male > 40g/d, female > 20g/d; Autoimmune hepatitis has a simplified scale score of ≥6 or a complex scale score of ≥10, or is not distinguishable from autoimmune hepatitis; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-26 00:00:00至 To 2025-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-12-26 00:00:00 至 To 2025-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
评估者采用NumPy方法产生随机数列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Evaluators use NumPy method to generate random sequences |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label study |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表论文、专利公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publish papers and make patents public |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无CRF、EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
no CRF or EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |